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Abstract
Recent advancements in mass spectrometric proteomics provide a promising result in utilizing saliva to explore
biomarkers for diagnostic purposes. However, the issues of specificity or redundancy of disease-associated
salivary biomarkers have not been described. This systematic review was therefore aimed to define and sum-
marize disease-related salivary biomarkers identified by mass spectrometry proteomics. Peer-reviewed articles
published through July 2009 within three databases were reviewed. Out of 243 articles, 21 studies were selected
in this systematic review with conditions including Sjögren’s syndrome, squamous cell carcinoma, dental caries,
diabetes, breast cancer, periodontitis, gastric cancer, systemic sclerosis, oral lichen planus, bleeding oral cavity,
and graft-versus-host disease. The sample size ranged from 3–41 in both diseased and control subjects, with no
consensus on sample collection protocol. One hundred eighty biomarkers were identified in total; 87 upregu-
lated, 63 downregulated, and 30 varying based on disease. Except for Sjögren’s syndrome, the majority of
studies with the same disease produce inconsistent biomarkers. Larger sample size and standardization of
sample collection/treatment protocol may improve future studies.
Introduction
Whole saliva is mainly composed of fluid producedby major and minor salivary glands. Major salivary
glands including parotid, submandibular, and sublingual
glands, are known to secrete fluid transported from serum
as well as surrounding glandular tissues. This selective
transportation within salivary glandular tissue is regulated
by both acinar and tubular epithelial cells. Beside the se-
cretions from salivary glands, oral mucosa, periodontium,
as well as oral microflora also contribute to the final content
of whole saliva. Whole saliva therefore represents a com-
plex balance among local and systemic sources. This allows
for the application of saliva in the diagnosis not only for
salivary gland disorders but also for oral diseases and
systemic conditions (Caporossi et al., 2010; Good et al.,
2007; Hu et al., 2007a; Lee et al., 2009).
The noninvasive and simple nature of saliva collection al-
lows for repetition and multiple collection of saliva that can
potentially aid in early diagnosis, monitoring disease pro-
gression, or treatment responses with minimally trained
personnel. This advantage of using saliva attracts investiga-
tors who look for an alternative form of body fluids to sim-
plify a diagnostic procedure (Giusti et al., 2007; Hu et al.,
2007b; Peluso et al., 2007). In the past decade, development of
mass spectrometric technologies led us to a new era in bio-
marker discovery that potentially will have a huge impact on
future disease diagnosis and therapy. Mass spectrometry
(MS) allows us to examine a salivary proteome in minute
details. The presence or absence, level of expression, as well as
posttranslational modifications of multiple biomarkers in a
salivary proteome theoretically altered by diseases or inter-
ventions can be detected with modern MS (Caporossi et al.,
2010; Good et al., 2007; Hu et al., 2007a; Lee et al., 2009).
Although there are numerous MS-based proteomic studies
of serum or plasma, limited numbers of salivary proteomic
studies are available. This systematic review, therefore, aims
to critically review relevant clinical MS-based proteomic
studies of human saliva in order to compare and contrast
salivary biomarkers. In order to determine if identified bio-
markers are specific to a particular disease, we compared and
summarized mass spectrometry methods and identified dis-
ease-associated salivary protein biomarkers within the same
group of diseases/disorders, as well as among different dis-
eases/disorders. In addition, comparing these studies would
allow for a more meaningful comparison of the results from
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different studies and provide collection of experimental pro-
tocols and disease-associated salivary biomarkers.
Methods
To complete the review, two reviewers (S.K.A., a senior
prosthodontic resident, and S.B., a prosthodontic/pharmacology
faculty member) completed two independent searches using
the determined databases. The search was completed through
July 2009 in the following databases: PubMed (1950 to date),
using the following words: [salivary (All Fields) OR ‘‘saliva’’
(MeSH Terms) OR ‘‘saliva’’ (All Fields)] AND [‘‘proteomics’’
(MeSH Terms) OR ‘‘proteomics’’ (All Fields) OR proteomic
(tw) OR ‘‘proteome: (MeSH Terms) OR ‘‘proteome’’ (All
Fields)], EMBASE via OVID (1988 to date) using: (Proteo-
mic.mp., exp proteomics/or proteomics.mp., saliva analysis/
or saliva.mp. or saliva/ or saliva protein, salivary .mp., and
proteome.mp. or proteome), and BIOSIS Previews via ISI Web
of Science (1969 to date), ISI Citation via ISI Web of Science
(1955 to date) using the following words: Saliva* AND pro-
teome*. Abstracts of all articles found using the prescribed
protocol were reviewed. Review articles, opinions, case reports,
letters to the editors, news, and articles merely describing a
technique were excluded. Only studies using human saliva
were included. From the remaining research articles, only
studies using MS-proteomics to compare the salivary pro-
teomes from a disease group and a control group were selected
for full text review. Only articles in the English language were
included. The final articles were selected with the agreement of
the first two reviewers. The third reviewer (M.B.B., a senior
undergraduate predental student majoring in biochemistry)
was asked to review the article when there was a disagreement
between the first two reviewers. Each article was then ab-
stracted. Information on subject population, salivary sample
collection and processing, mass spectrometry technique used,
as well as biomarkers identified was included in the abstract.
Results
A total of 243 articles resulting from database searches were
reviewed. The database search process, excluded and in-
cluded articles, as well as reasons for the exclusion are shown
in Figure 1. Twenty-one articles were selected for full text
review and abstracted, with information (disease, sample
size, saliva type collected, selection of controls, analytical
method utilized, and biomarkers identified) documented in
Tables 1 and 2 and Supplementary Table 1 (Dowling et al.,
2008; Fleissig et al., 2009; Giusti et al., 2007a, 2007b; Hirtz et al.,
2006; Hu et al., 2007b, 2007c, 2008; Huang, 2004; Imanguli
et al., 2007; Ohsiro et al., 2007; Peluso et al., 2007; Preza et al.,
2009; Rao et al., 2009; Ryu et al., 2006; Streckfus et al., 2006,
2008; Vitorino et al., 2006; Wu et al., 2009a, 2009b; Yang et al.,
2006). This systematic review is the first to evaluate the MS-
based proteomic studies that utilized saliva to define bio-
markers related to specific diseases. Results suggest that the
type of saliva collected, saliva collection and handling pro-
cess, proteomic techniques, and biomarker validation must be
addressed to enhance the use of MS technology.
Type of saliva collected
Variations in saliva collection can yield different proteomic
profiles and, as a result, different biomarkers. From our
review, there are two important issues in saliva collection that
may influence proteomic biomarkers; whole saliva versus
individual gland saliva, and unstimulated versus stimulated
saliva.
First, in assessing whole saliva versus individual gland
saliva, a majority of studies chose to use whole saliva. Nine-
teen out of 21 studies used whole saliva samples (Table 1),
representing a complex fluid from both local and systemic
sources (Caporossi et al., 2010). This could have possible ap-
plications in the diagnosis of oral diseases, salivary gland
disorders, and systemic conditions (Lee et al., 2009). Whole
saliva collection will presumably be a composition of fluids
from all major and minor salivary glands, as well as fluids
from mucosal and periodontal tissues. In addition, whole
saliva will also be largely influenced by oral environments,
such as particular oral health problems/conditions. In studies
of host immune responses in oral and systemic disease, it may
be more beneficial to collect whole saliva. In addition to this,
collection of whole saliva is more simple and requires mini-
mal equipment. On the other hand, collection of individual
gland saliva provides a more controlled fluid. It requires more
sophisticated equipment and, therefore, is more difficult than
whole saliva collection. Collection of individual gland saliva
can, however, provide more specific information regarding
diseases of particular salivary glands and may have little in-
fluence from the other part of the oral cavity. Only four
studies in our review utilized individual gland saliva collec-
tion.
Second, in assessing the use of unstimulated or stimulated
saliva, whole saliva can be stimulated or unstimulated, which
differ in areas such as the ratio of contribution of major sali-
vary glands and concentration of certain proteins, ions, and
water (Ohsiro et al., 2007). Unstimulated saliva is believed to
represent an equilibrated condition, having less influence
from salivary glands. However, in some cases it was sug-
gested that stimulated saliva may provide a more accurate
FIG. 1. A flow chart for the search results from each data
base, and inclusion and exclusion criteria.


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































detection of cancer biomarkers (Streckfus and Dubinsky,
2007). In some conditions where salivary flow is reduced or
there is xerostomia, such as in Sjögren’s syndrome or post-
radiation, stimulating saliva collection may be required to
obtain optimal amounts of saliva samples.
Although it is widely believed that different types of saliva
(whole vs. individual gland saliva collection, and un-
stimulated vs. stimulated saliva) may give rise to the dis-
covery of different biomarkers, this seems to not be the case
for at least Sjögren’s syndrome. Three out of five studies on
Sjögren’s syndrome used unstimulated whole saliva (Table 1),
whereas the other two studies used stimulated saliva from
individual glands. Although this collection protocol is clearly
different, we found the most consistent biomarker findings
among these five studies in Sjögren’s syndrome (Table 2). This
may have been due to the fact that Sjögren’s syndrome is
directly involved with salivary glands itself and may not be
applicable to nonsalivary gland diseases.
Saliva collection and handling process
The relevance of avoiding changes in body fluid samples
after sample collection is well recognized (Messana et al.,
2008). Factors such as specimen collection, handling, and
processing (such as the common use of protease inhibitors)
affect the success of proteomic studies. Although simplicity of
sample collection is often advocated as a major advantage in
using saliva as a diagnostic fluid, some precautions need to be
taken in saliva collection.
First, unlike serum, saliva is susceptible to many physio-
logical and biochemical processes, both locally and systemi-
cally (Helmerhorst and Oppenheim, 2007). Salivary contents
can be altered as a result of physiological processes occurring
at different points during the day, as well as due to oral
stimuli (Caporossi et al., 2010). The majority of studies in our
review required subjects to refrain from oral stimuli such as
eating, drinking, and oral hygiene practices for varied periods
of time prior to sample collection. For data to be meaningful,
saliva must be collected under standardized conditions due to
the presence of circadian rhythms in salivary flow rate and
compositional influences.
Second, whole saliva can contain a considerable amount of
shed epithelial cells, microorganisms, and remnants of food
and liquid ingestion, making it essential to centrifuge whole
saliva samples to remove extraneous material. This was re-
flected in the reviewed studies where centrifugation, with
speeds varying among studies, was performed at some point
within the protocol. In 12 studies in this review, the samples or
the resulting supernatant after centrifugation were stored at
808C. Two studies had them stored at708C, two at208C.
In five studies the samples were processed immediately. To
avoid artifacts as a result of sample degradation, time elapsed
between sample collection and analysis was minimized.
Shortening the elapsed time to 5 min, and treating samples
Table 2. Summary of the Commonly Identified Biomarkers for Each of the Diseases Investigated
Disease
Biomarkers commonly
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with TFA (triflouroacetic acid) or other protease inhibitiors
prior to centrifugation and sample storage was recommended
(Messana et al., 2008). Studies have indicated storage at
808C to be better than at 208C, especially after storage for
prolonged times (Schipper et al., 2007). Saliva samples are
composed of several proteases. These proteases potentially
degrade protein biomarkers. It has been shown that leaving
saliva samples for a period of time can alter proteomic profiles
and change the biomarker content (Al-Tarawneh and
Bencharit, 2009). Shortening the time of storage before cen-
trifugation, fast frozen (with dried ice or liquid nitrogen),
storing the samples in low temperature (808C), and avoiding
multiple freeze–thaw processes, as well as consistent sample
collection protocol, are known to enhance consistent pro-
teomic analytical results and the degradation of sensitive
protein biomarkers (Schipper et al., 2007).
Finally, large amounts of glycosylated proteins present in
saliva often make sample handling during analysis challeng-
ing, in particular, proteomic analysis. These glycoproteins
make saliva a glue-like consistency, contributing to difficulty in
sample manipulation. Glycosylated biomarkers are possibly
more stable and not easily degraded when compared to non-
glycosylated proteins. Due to increases in salivary glycoprotein
volume, chromatrographic column use may provide data
dense with those glycosylated species and void of other po-
tential biomarkers (Ramachandran et al., 2006).
Selection of controls
Selection of appropriate controls is essential to avoid false
identification of biomarkers due to nondisease related dif-
ferences between the control and the diseased groups.
Regarding selection of control groups, some of the studies did
not indicate specific inclusion and exclusion criteria, whereas
others followed specific protocols including: absence of clin-
ical symptoms related to the disease in question (Fleissig et al.,
2009), enrolling individuals with similar mean age and de-
mographic characteristics to the diseased group (Giusto et al.,
2007a, 2007b; Hu et al., 2007b, 2007c) using matched siblings
(Imanguli et al., 2007), and negative findings in tests specific
to the disease (Peluso et al., 2007; Ryu et al., 2006).
Proteomic techniques
Analysis of human saliva proteomes is inherently chal-
lenging because the salivary proteome contains a large
number of proteins within an extremely wide concentration
range. Initial biomarker fractionation is required for MS-
based proteomic techniques. Each fraction or spot is subjected
to certain mass-spectrometric technology. The resulting mass
data is then used to search protein, genomic, expressed se-
quence tag (EST), and other species-specific databases to
identify proteins present in each selected spot. By comparing
samples, changes in the level of expression of individual
proteins can be detected and quantified, permitting the
identification of biomarkers associated with specific patho-
logic or physiologic states of a cell or tissue. Our review
shows that there are four different techniques used (at times
in combination) in biomarker screening and identification.
These include 2DE, 2D-liquid chromatography/mass spec-
trometry (LC/MS), matrix-assisted laser desorption ionization–
time of flight/mass spectrometry (MALDI-TOF/MS), and
surface enhanced laser desorption/ionization time-of-flight
mass spectrometry (SELDI-TOF/MS) (Supplementary
Table 2).
2DE (two-dimensional gel electrophoresis), a combination
of SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel
electrophoresis), and IEF (isoelectric focusing), is capable of
separating and resolving complex protein mixtures, enabling
the visualization and identification of several thousand pro-
teins on a single gel. The drawbacks, however, of 2DE include
poor gel-to-gel reproducibility, large amounts of required
sample, time required, extensive labor, and low sensitivity.
Our systematic review (Supplementary Table 2) suggests that
2DE is still the most popular technique for the global analysis
and initial profiling of saliva prior to further fractionation and
identification with other high throughput techniques. Most
studies used 2DE as a first step for protein separation, fol-
lowed by tandem MS (MS/MS).
The second method used is the 2D-LC/MS or the mul-
tidimensional protein identification technology (MudPIT)/
shotgun and the subsequent search of large-scale databases
such as SEQUEST and MASCOT. Liquid chromatography
methods coupled with MS or LC-MS/MS are suitable for
separation and identification of low-molecular-weight
components. However, this technique still has the disad-
vantages of being labor intensive and provides limited in-
formation about the relative abundance of the detected
proteins. Improvement of chromatographic technology
allows for increased high throughput capacity of this
technique.
The MALDI-TOF/MS technique is an improvement in
terms of its high sensitivity for a large mass range and sim-
plicity of interpretation of the mass spectra (Ramanchandran
et al., 2006). This technique was used in some studies for initial
profiling prior to further identification using LC-MS tech-
niques, whereas in other studies it has been used as the main
identification technique after initial profiling with 2DE (Sup-
plementary Table 2). In some cases the SELDI-TOF/MS
technique where the sample matrix (Protein Chip) has an
active role in sample purification, desorption/ionization, and
protein separation] was used to quantify and reproduce re-
sults (Al-Tarawneh and Bencharit, 2009).
Biomarker discovery and validation
A biomarker is defined as a pharmacological or physio-
logical measurement that is used to predict a toxic event; a
specific molecule in the body, which has a particular feature
that makes it instrumental for measuring disease progression
or the effects of treatment. Biomarkers are by definition suit-
able to develop new diagnostic tools, alone or in combination
with traditional methods (Brinkman and Wong, 2006). It is
essential to choose the proper sample type, processing and
handling, and proteomic techniques that will be used prior to
initiation of biomarker discovery, as these techniques differ
tremendously based on the intended biomarkers (Streckfus
and Dubinsky, 2007). From this review, several techniques
were used for biomarker discovery and quantification after the
initial profiling such as two-dimensional difference gel elec-
trophoresis mass spectrometry (2D-DIGE-MS), label free LC-
MS/MS, and isobaric tagging for relative and absolute quan-
titation (iTRAQ) labeling prior to MS/MS quantification. In
this review, some studies expressed the results of proteomic
identification and quantification as a number of the differentially
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expressed peaks or spots of peptides or proteins, whereas
others further identified those differentially expressed bio-
markers to the specific corresponding proteins (Supplemen-
tary Tables 1, 2, and 3).
Discussion
Collecting saliva is often perceived as being distasteful by
research subjects, as well as clinician researchers. Although
we found that from our review the issue of compliance of
subjects and researchers was not addressed in any of the se-
lected articles, it is important to note that most salivary pro-
teomic research has been done in academic institutes that deal
with oral heath, in particular, dental schools. Note also that for
several of these studies, the final research goal is to seek a
simple, noninvasive, and relatively inexpensive diagnostic
salivary tool. These rationales are perhaps some of the best
arguments for advocating salivary proteomic biomarker dis-
covery research.
Although our application of systematic review to pro-
teomic studies is unconventional, similar studies appear in the
current literature. For example, Atiomo et al. (2009) used
systematic review to describe the biomarkers for polycystic
ovary syndrome. Liu et al. (2011) similarly utilized systematic
review to define common biomarkers associated with Hepa-
tocellular carcinoma. We believe that utilizing systematic re-
view to evaluate salivary proteomic/biomarker discovery
studies may allow for future improvement in this rapidly
growing field and may facilitate the development of saliva as
a diagnostic fluid in the future.
Ultimately, 180 differentially expressed biomarkers were
identified (Supplementary Tables 1 and 3). Of these, 87 were
found to be upregulated, 63 downregulated, and 30 were
found to vary based upon the disease investigated. For ex-
ample, Cystatin SA-III was found to be upregulated in each
reviewed case of breast cancer, bleeding oral cavities, and
Sjögren’s syndrome (Supplementary Table 3). Its upregula-
tion makes it a valuable biomarker for indicating instances of
disease progression, but due to the nonspecificity of its ex-
pression in terms of disease type, its development into a di-
agnostic tool may not be the most promising.
Similarly, looking at Acidic PRP-1 1P, its expression is
downregulated in each reviewed case of Sjögren’s syndrome,
and type 1 diabetes (Supplementary Table 3). Just as with
those biomarkers continually upregulated, this biomarker’s
constant downregulation makes it valuable for general iden-
tification of disease progression, but lacks the desired level of
specificity needed to be developed into an effective diagnostic
tool.
Alpha-amylase is representative of biomarkers whose ex-
pression varies based on the disease in question, being upre-
gulated in cases of dental carries, Sjögren’s syndrome,
periodontitis, and graft-versus-host disease, while being
downregulated in type 1 diabetes (Supplementary Table 3).
Its more closely specific directions of expression make it more
applicable as a biomarker to be developed as a diagnostic tool;
however, specificity issues still arise, albeit to a lesser degree.
Overall, the identified biomarkers and their expression
demonstrate the potential use of a combination of significant
biomarkers to structure a more complete diagnostic tool. The
potential exists for combinations of identified biomarker ex-
pression, or the correlation of biomarker expression and
clinical assessments, to be utilized to achieve effective disease
diagnosis. In 11 of the studies, the identified biomarkers were
further validated. Immunoassays such as ELISA and Western
blotting were used in the majority of the studies (Supple-
mentary Table 2). In the case of clinical proteomics, it is likely
that multiple novel candidates will be identified, meaning
multiple reaction monitoring/stable isotope dilution (MRM/
SID–MS) using quadruple MS may allow for greater
throughput, accuracy, and sensitivity than antibody devel-
opment (Rifai et al., 2006). We found that, except for Sjögren’s
syndrome, few biomarkers were found to be common in
different studies of the same disease. This can be attributed to
inconsistencies in saliva collection and processing protocols,
small sample numbers, as well as differences in MS platforms
(Table 2).
Analyses of normal human salivary proteomes compared
with diseased proteomes should demonstrate molecular
profiles that lead to disease-specific molecular biomarkers.
However, this trend has not been the case in most of the sal-
ivary proteomic studies. Whole saliva represents a complex
fluid as a result of contribution from both local and systemic
sources. Unlike plasma, once saliva is secreted into the oral
cavity, little regulation from the host can be achieved. Oral
microflora and tissues also play an important role in this
complexity. Changes in salivary proteomes resulting from
diseases or disorders that may be measured as a significant
change may not be disease/disorder-specific. There are two
important issues concerning the validity of salivary proteomic
analyses and the discovered biomarkers. These include (1)
sample treatments and mass spectrometry analysis methods,
and (2) nature of the disease.
To address the first issue, future studies must include larger
samples of patients and follow a standardized protocol. Va-
lidation of novel biomarkers is of paramount value, especially
when use as a diagnostic tool for personalized medicine based
on these biomarkers is the final goal. Although salivary pro-
teomics are increasingly widely used, there are several issues
that must be addressed in future studies. These include a
standardized protocol in saliva sample collection, unification
in treatment protocol, and differences in the use of analytical
methods. Future studies must also focus on the use of a
standardized protocol for data analysis. Ultimately, a larger
sample size is required for validation and generalization of
results in future salivary proteomic studies.
Even with using the same samples, different sample
treatments/collection protocols and mass spectrometry pro-
teomic platforms can result in completely different biomarker
profiles. Recent methodology reviews suggest methods that
are carefully planned and standardized. This may help reduce
the differences within the study and allow for a more mean-
ingful comparison among studies (Henson and Wong, 2010;
Hu et al., 2010; Loo et al., 2010; Ohshiro et al., 2007).
Several of the biomarkers listed here and detected by MS-
based proteomic techniques have been discussed elsewhere in
the literature to be detected with different techniques such as
the use of Western blotting in detection of Psoriasin (S100A7)
as a potential predictor of pulmonary involvement in systemic
sclerosis (Baldini et al., 2008a,b). Lactoferrin and beta-2-
microglobulin and cystatin have been shown to be biomarkers
for Sjögren’s syndrome using ELISA, and enzyme inhibition
assays (Carpenter et al., 2000). As for breast cancer related
biomarkers, C-erbB-2, and epidermal growth factor (EGF)
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were investigated previously using ELISA and western blot-
ting (Bigler et al., 2002; Brooks et al., 2008; Steckful and Bigler,
2005). Lactoferrin detection has been related to periodontitis
(Komine et al., 2007), type 2 diabetes mellitus (Dodds et al.,
2000), and Sjögren’s syndrome both by ELISA and Western
blotting (Carpenter et al., 2000). Although only a few bio-
markers are confirmed by other methods, several biomarkers
found in most studies were not confirmed by other analyses or
by other non-MS methods.
Based on a combination of all salivary biomarkers, we can
divide biomarkers into three categories: (1) biomarkers spe-
cific to a disease, (2) biomarkers that are nonspecific to a
disease but seems to demonstrate an abnormal condition, and
(3) biomarkers that are randomly seen that may be a result of
diversities or variations between control-diseased samples,
sample treatment protocols, and mass spectrometry plat-
forms.
Aside from the fact that we are interested in variations/
similarities in sample collections and analytical protocols, our
rationale to include all mass spectrometry-based salivary
proteomics regardless of how diverse the conditions/disease
was that we want to answer two important questions. First,
are there any specific salivary biomarkers for a certain con-
dition or disease? Second, are there any salivary biomarkers
that may not be specific for a disease but the changes in these
particular biomarkers alarm an abnormal condition?
Although in a conventional sense, one may believe that
there should be a specific biomarker for a certain disease. This
may be true in many diseases, for example, particular breast
cancer cells express specific proteins including C-erbB-2 and
EGF (Bigler et al., 2002; Brooks et al., 2008; Streckfus and
Bigler, 2005). Unfortunately, most diseases/conditions that
are included in our collection (perhaps except for Sjogren’s
syndrome), are within themselves a collection of diseases/
conditions. For example, an oral cancer even only for squa-
mous cell carcinoma, could range from a carcinoma in situ, to
a frank cancerous lesion to a metastasized tumor. Even worse,
in caries or periodontal disease, these conditions can be
caused by numerous factors, from variations in microorgan-
isms to host responses. Our oral diseases are hardly homog-
enous as one may assume.
It is interesting to examine the discrepancies in identified
biomarkers in similar diseases, for example, root caries and
caries. There were virtually no common biomarkers between
these two studies (Preza et al., 2009; Vitorino et al., 2006)
(Table 1 and Supplementary Tables 1, 2, and 3). This fact could
be attributed to the following reasons. First, the investigators
used different types of collected saliva and collection protocol.
The root caries group used stimulated parotid saliva, whereas
the caries group used unstimulated whole saliva. It is possible
that whole saliva content would be different from individual
gland saliva in terms of contribution from other sources in the
oral cavity (see Results, Type of saliva collected). Second, the
proteomic methods are clearly different. The former group
used SDS-PAGE and LC-MS/MS, whereas the latter used 2D
gel electrophoresis (2-DE) and MALDI-TOF/MS. Clearly
results differ both in in the number of identified biomarkers
and the identities of the biomarkers. 2-DE will clearly give
better biomarker separation (based on both charge and mass)
and, therefore, yields a higher number of biomarkers (14
biomarkers in root caries study, Preza et al., 2009; and 44 in
caries study, Vitornio et al., 2006). This type of difference is
also reflected in other studies. Note that in more recent
studies, applications of different version of chromatography
(e.g., SELDI-TOF/MS, HPLC, and other affinity chromatro-
graphy) appear to provide larger amounts of biomarkers.
Finally, biomarker validation remains very different in these
two studies. Western blotting was used in the root caries
study, whereas the caries study did not provide any second-
ary methods. Traditionally, antibody-based methods, includ-
ing Western blotting, ELISA, and multiplex, are recommended
to validate the presence of biomarkers. However, these
methods require the availability of certain antibodies. It is
possible that there may be no antibody available for novel
biomarkers. If there are antibodies specific for a particular
biomarker, they may or may not interact with the MS identi-
fied biomarkers because the antibody detection requires the
presence of a specific antigenic epitope. Several recent MS
based biomarker discoveries may not report a few biomark-
ers with confirmation from antibody-based assays but usu-
ally report most unconfirmed biomarker hits from database
searches.
Conclusions
Current literature suggests that increasing sample size and
utilizing a controlled/standardized protocol can improve
future salivary proteomic research. Confirmation of bio-
markers should be done with more than one analytical plat-
form. Alterations of certain salivary biomarkers, either
disease-specific or disease-nonspecific, may allow a molecular
insight that possibly precedes or coincides with clinical
changes. Taking all this into account, examination of both
disease-specific and disease-nonspecific biomarkers may,
therefore, allow us to develop a salivary proteomic-based
diagnostic tool. Careful clinical evaluation of particular pa-
tients and evaluation of salivary biomarkers, along with other
clinical parameters, may advance our utilization of salivary
diagnostics as a paramedical diagnostic tool.
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